I think you are wrong about how the public will receive future data. (Hopefully) the screw up was NOT THEIR FAULT at PPHM.
Since Avid manufactures bevacizumab, I sure the heck hope they didnt send out the wrong DRUG. I've never like the fact the 2 drugs are so close in spelling, bavituxumab, bavacizumab.
I listened to the previous conference call to hear the excitement over the results of phase 2. If it is proven NOT THEIR FAULT and the results remains good is what I want to hear and the investment community and the partnering companies.
If pancreatic trial is a good one, great for patients with so little choice of treatment and a death sentence of a diagnosis, great for company and great for investors and interested partners.
Each indication validated increase share value in the future. Breast, Lung, Pancreatic worth how many BILLIONS in the future. We know from prior trial something, it works!